Compare ADT Inc (ADT) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADT Inc vs Summit Therapeutics Inc — how do they compare? ADT Inc trades at $7.37 (market cap $5.44B), while Summit Therapeutics Inc trades at $15.1 (market cap $12.06B). The key difference: Summit Therapeutics Inc is far larger — about 2.2× ADT Inc's market cap, and ADT Inc pays a 2.95% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ADT | SMMT | |
|---|---|---|
Market Cap | $5.44B | $12.06B |
Sector | Industrials | Health |
52-Week High | $8.85 | $26.98 |
52-Week Low | $6.30 | $12.55 |
Enterprise Value | $13.13B | $11.39B |
Dividend Yield | 2.95% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADT trades at $7.33, down 2.4% today, with a bullish technical signal from moving averages. The company reported Q2 2026 EPS of $0.23, beating estimates, and maintains strong cash flow. Valuation ratios appear attractive with a P/E of 10.35 and EV/EBITDA of 4.93. Recent news highlights a Zacks upgrade to Buy and institutional stake increases.
Outlook is positive due to consistent earnings beats and solid profitability, but risks include high debt levels and competitive pressures. Analysts are generally bullish, with 47% recommending Buy. The stock offers value with growth potential from AI integration and shareholder returns via dividends and buybacks.
Summit Therapeutics (SMMT) trades at $15.10, up 1.55% with a bullish technical signal and strong analyst support. The company shows negative profitability metrics with ROE at -192.5% and net income of -$1.08B for 2025, but maintains positive cash flow through financing activities. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials, driving investor optimism despite ongoing losses.
The investment case hinges on ivonescimab's regulatory approval potential, with a consensus price target of $27.90 representing 85% upside. Key risks include cash burn concerns, fiduciary duty investigations, and clinical trial outcomes. While fundamentals remain weak, the stock offers high-risk, high-reward potential for speculative biotech investors betting on successful drug commercialization.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ADT Inc
ADT Inc is a provider of monitored security, interactive home and business automation, and related monitoring services in the United States and Canada. ADT offers residential, commercial, and multi-site customers a comprehensive set of burglary, video, access control, fire and smoke alarm, and medical alert solutions. It provides interactive home and business automation solutions designed to control access, react to movement, and sense carbon monoxide, flooding, changes in temperature or other environmental conditions, as well as address personal emergencies, such as injuries and medical emergencies. In addition, it offers professional monitoring of third-party devices through ADT Canopy platform. The product brands of the company are ADT and ADT Pulse, and Protection One brand.
Read more on ADT →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
